Case Study: Patient with MF has Increasing Blasts, but Not Yet AML -- What to Do? John Mascarenhas, MD Myeloproliferative Disorders Program Tisch Cancer.
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results 1 Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis:
Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.
1 Komrokji RS et al. Proc ASH 2011;Abstract 282.
